Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. Show more

Location: 7 Golda Meir Street, Ness Ziona, 7403650, Israel | Website: https://www.sol-gel.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

22.67M

52 Wk Range

$3.34 - $16.50

Previous Close

$8.11

Open

$8.19

Volume

3,552

Day Range

$7.90 - $8.19

Enterprise Value

4.892M

Cash

16.9M

Avg Qtr Burn

N/A

Insider Ownership

70.00%

Institutional Own.

24.29%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.